WO2005015206A3 - Secreted polypeptide species associated with cardiovascular disorders - Google Patents

Secreted polypeptide species associated with cardiovascular disorders Download PDF

Info

Publication number
WO2005015206A3
WO2005015206A3 PCT/EP2004/008860 EP2004008860W WO2005015206A3 WO 2005015206 A3 WO2005015206 A3 WO 2005015206A3 EP 2004008860 W EP2004008860 W EP 2004008860W WO 2005015206 A3 WO2005015206 A3 WO 2005015206A3
Authority
WO
WIPO (PCT)
Prior art keywords
cardiovascular disorders
secreted polypeptide
species associated
polypeptide species
polypeptides
Prior art date
Application number
PCT/EP2004/008860
Other languages
French (fr)
Other versions
WO2005015206A2 (en
Inventor
Guilaine Argoud-Puy
Nassima Bederr
Lydie Bougueleret
Isabelle Cusin
Eva Mahe
Anne Niknejad
Samia Reffas
Keith Rose
Cedric Saudrais
Andreas Scherer
Ruben Papoian
Original Assignee
Genova Ltd
Novartis Ag
Novartis Pharma Gmbh
Guilaine Argoud-Puy
Nassima Bederr
Lydie Bougueleret
Isabelle Cusin
Eva Mahe
Anne Niknejad
Samia Reffas
Keith Rose
Cedric Saudrais
Andreas Scherer
Ruben Papoian
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genova Ltd, Novartis Ag, Novartis Pharma Gmbh, Guilaine Argoud-Puy, Nassima Bederr, Lydie Bougueleret, Isabelle Cusin, Eva Mahe, Anne Niknejad, Samia Reffas, Keith Rose, Cedric Saudrais, Andreas Scherer, Ruben Papoian filed Critical Genova Ltd
Priority to JP2006522332A priority Critical patent/JP2007501605A/en
Priority to EP04763890A priority patent/EP1654545A2/en
Publication of WO2005015206A2 publication Critical patent/WO2005015206A2/en
Publication of WO2005015206A3 publication Critical patent/WO2005015206A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Physics & Mathematics (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Emergency Medicine (AREA)
  • Food Science & Technology (AREA)
  • Obesity (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Nutrition Science (AREA)

Abstract

The invention discloses human secreted polypeptides that circulate at an increased level in the plasma of patients with cardiovascular disorders. The invention also provides methods of using compositions including the polypeptides, polynucleotides encoding them, and antibodies specific for these polypeptides, for diagnosis, prognosis, and for drug development.
PCT/EP2004/008860 2003-08-08 2004-08-06 Secreted polypeptide species associated with cardiovascular disorders WO2005015206A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2006522332A JP2007501605A (en) 2003-08-08 2004-08-06 Secreted polypeptide species associated with cardiovascular disease
EP04763890A EP1654545A2 (en) 2003-08-08 2004-08-06 Secreted polypeptide species associated with cardiovascular disorders

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US49386703P 2003-08-08 2003-08-08
US49383603P 2003-08-08 2003-08-08
US49398503P 2003-08-08 2003-08-08
US49359903P 2003-08-08 2003-08-08
US60/493,985 2003-08-08
US60/493,867 2003-08-08
US60/493599 2003-08-08
US60/493,836 2003-08-08

Publications (2)

Publication Number Publication Date
WO2005015206A2 WO2005015206A2 (en) 2005-02-17
WO2005015206A3 true WO2005015206A3 (en) 2005-06-09

Family

ID=34139822

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2004/008860 WO2005015206A2 (en) 2003-08-08 2004-08-06 Secreted polypeptide species associated with cardiovascular disorders

Country Status (3)

Country Link
EP (1) EP1654545A2 (en)
JP (1) JP2007501605A (en)
WO (1) WO2005015206A2 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007116199A1 (en) * 2006-04-07 2007-10-18 Imperial Innovations Limited Methods and reagents for diagnosing heart failure
GB0916578D0 (en) * 2009-09-22 2009-10-28 Malmsten Nils M Polypeptides and uses thereof
US9140692B1 (en) * 2010-01-08 2015-09-22 Glycozym, Inc. Methods of identifying glycopeptides recognized by disease-associated auto-antibodies
EP2399598B1 (en) * 2010-06-28 2014-08-06 Universitätsklinikum Freiburg Blockade of CCL18 signaling via CCR6 as a therapeutic option in fibrotic diseases and cancer
DK2585089T3 (en) 2010-06-28 2016-12-12 Universitätsklinikum Freiburg CCL18 blockade of signaling through CCR6 as a therapeutic option in fibrotic diseases and cancer
JP2012223107A (en) * 2011-04-15 2012-11-15 Akira Matsumoto Peptide being pathologic condition marker/remedy, and use thereof
WO2015011073A1 (en) * 2013-07-25 2015-01-29 F. Hoffmann-La Roche Ag Autoimmune derived antibodies to dermcidin as cardiovascular risk markers
GB201322574D0 (en) * 2013-12-19 2014-02-05 Equigerminal Sa Retroviral peptides
KR102499670B1 (en) * 2019-06-17 2023-02-20 고려대학교 산학협력단 Romo1-derived antimicrobial peptides containing lysine substitution and variants thereof
US20220259265A1 (en) * 2019-07-30 2022-08-18 The University Of Sydney Inhibitors and Use Thereof in Cancer Treatment

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5432261A (en) * 1989-01-06 1995-07-11 Sanwa Kagaku Kenkyusho Co. Ltd. Motlin-like polypeptide and use thereof
WO2002088750A2 (en) * 2001-05-02 2002-11-07 Oxford Glycosciences (Uk) Ltd Proteins, genes and their use for diagnosis and treatment of breast cancer
WO2004082568A2 (en) * 2003-03-17 2004-09-30 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with complement component 5a receptor (c5ar)

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5432261A (en) * 1989-01-06 1995-07-11 Sanwa Kagaku Kenkyusho Co. Ltd. Motlin-like polypeptide and use thereof
WO2002088750A2 (en) * 2001-05-02 2002-11-07 Oxford Glycosciences (Uk) Ltd Proteins, genes and their use for diagnosis and treatment of breast cancer
WO2004082568A2 (en) * 2003-03-17 2004-09-30 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with complement component 5a receptor (c5ar)

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
AMERICAN JOURNAL OF PHYSIOLOGY, vol. 267, no. 4 PART 2, 1994, pages H1288 - H1294, ISSN: 0002-9513 *
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, vol. 20, no. 3, March 2000 (2000-03-01), pages 698 - 702, ISSN: 1079-5642 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 1994, ITO BRUCE R ET AL: "Effect of platelet depletion and inhibition of platelet cyclooxygenase on C5a-mediated myocardial ischemia", XP002311909, Database accession no. PREV199598001774 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 1996, ENSKOG ANDERS ET AL: "Complement anaphylatoxin C3a and C5a formation in premature children with respiratory distress", XP002311910, Database accession no. PREV199698649338 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; March 2000 (2000-03-01), HOLVOET PAUL ET AL: "Oxidized low density lipoprotein is a prognostic marker of transplant-associated coronary artery disease", XP002311911, Database accession no. PREV200000157296 *
EUROPEAN JOURNAL OF PEDIATRICS, vol. 155, no. 1, 1996, pages 41 - 45, ISSN: 0340-6199 *

Also Published As

Publication number Publication date
WO2005015206A2 (en) 2005-02-17
EP1654545A2 (en) 2006-05-10
JP2007501605A (en) 2007-02-01

Similar Documents

Publication Publication Date Title
WO2003101401A3 (en) Use of nrg4, or inhibitors thereof, in the treatment of colon and pancreatic cancer
WO2004047755A3 (en) Fused bicyclic nitrogen-containing heterocycles
WO2004098377A3 (en) Methods and compositions for diagnosis and therapy of parkin-associated disorders
WO2006068987A3 (en) Uses of il-23 antagonists in the treatment of diabetes mellitus
WO2002060317A3 (en) Compositions and methods for the therapy and diagnosis of pancreatic cancer
WO2007059135A3 (en) Methods of treating alzheimer's disease
HK1177938A1 (en) Humanized anti-cmet antagonists c-met
WO2002074156A8 (en) Compositions and methods for the therapy and diagnosis of colon cancer
WO2004050017A3 (en) Rationally designed antibodies
WO2003087831A3 (en) Proteins involved in breast cancer
ZA200409492B (en) Compositions and methods for the diagnosis and treatment of tumor.
ZA200500882B (en) Polypeptides and nucleic acids encoding these and their use for the prevention, diagnosis of treatment or liver disorders and epithelial cancer
WO2002092001A3 (en) Compositions and methods for the therapy and diagnosis of lung cancer
WO2003104425A3 (en) Novel stable anti-cd22 antibodies
WO2004002431A3 (en) Humanized anti-lymphotoyin beta receptor antibodies
WO2005014635A3 (en) Secreted polypeptide species reduced in cardiovascular disorders
WO2005015206A3 (en) Secreted polypeptide species associated with cardiovascular disorders
GB0124145D0 (en) Genes and proteins for prevention,prediction,prognosis and therapy of cardiovascular disease
WO2002088750A3 (en) Proteins, genes and their use for diagnosis and treatment of breast cancer
WO2003037267A8 (en) Compositions and methods for the therapy and diagnosis of lung cancer
WO2004106941A3 (en) Secreted polypeptide species associated with cardiovascular disorders
WO2006024958A3 (en) Cannabinoid compositions and methods of use thereof
WO2005058251A3 (en) Hla-dr-specific antibodies, compositions and methods
WO2004090551A3 (en) Secreted polypeptide species associated with cardiovascular disorders
WO2004083241A3 (en) Btc-interacting proteins and use thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2004763890

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2006522332

Country of ref document: JP

WWP Wipo information: published in national office

Ref document number: 2004763890

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2004763890

Country of ref document: EP